The current interest rate environment is enticing companies to explore non-traditional financing. Royalty companies provide alternative financing structures which have real contractual income, alternative asset class features, and differentiated commodity exposure. Introducing the Tema #Royalties #ETF ($ROYA), an actively managed fund seeking to invest in listed royalty companies that provide structured exposure to revenue streams from commodities, pharmaceutical, entertainment and intellectual property assets. 🔹 Fund page: https://hubs.ly/Q01_j35r0 🔹 Learn more about how royalty companies can have highly efficient, profitable, and scalable business models: https://hubs.ly/Q01_j4NZ0 #ETFs #TemaETFs #Tema #investing #markets #activeETFs #activemanagement #thematicinvesting #ROYA #royalties #alternativefinancing
Tema ETFs’ Post
More Relevant Posts
-
Tema's scientific advisory board member, Professor Jens Juul Holst has released his new review article on GLP-1 treatments in obesity and weight loss. Check the full article out in Nature. https://lnkd.in/e_YRFMmf
To view or add a comment, sign in
-
Tema's CIO,Yuri Khodjamirian, CFA, has released the latest Q2 2024 CIO Investor Update which gives us a look back at each fund's performances, as well as what to expect within various industries. Check out the full report in the comments.
-
-
-
-
-
2
To view or add a comment, sign in
-
-
Healthcare investing can be complex. Having the backing of active and experienced Portfolio Managers can help with understanding not only the big players, but also the future of the GLP-1 market. Check out Maurits Pot break down the markets potential on Schwab Network in the comments below.
To view or add a comment, sign in
-
In a recent USA Today op-ed President Biden and Senator Sanders penned a stinging attack on the pricing of weight loss drugs calling the $1,100/month price tag “outrageous”. Check out Tema's perspective in the latest GLP-1 drug pricing blog! https://bit.ly/3SHlWBh
To view or add a comment, sign in
-
-
Tema's CIO, Yuri Khodjamirian, CFA chats to Ben Claremon on the Compounders podcast about our mission to provide quality access to ETF strategies and how we differentiate our ETFs within a crowded space. Check out the full podcast in the comments.
To view or add a comment, sign in
-
Maurits Pot joined Frank Holland on CNBC to discuss today's Eli Lilly's Q2 earnings. A third of Eli Lilly's revenue comes from GLP-1 drugs and with incredible demand, addressing the supply problem is the key to unlocking this market.
Worldwide Exchange (@CNBCWEX) on X
x.com
To view or add a comment, sign in